2019-09-13
2019-09-13
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
2019-09-14
2019-09-14
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
2019-09-15
2019-09-15
Plenary Hall
Ballroom A
Ballroom B
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
Plenary Hall
Ballroom A
Ballroom B
07:00 - 19:00
Registration
07:30 - 08:30
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate image
Allan B. Dietz, PhD (Chair)
Mayo Clinic, USA
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate image
Jacques Galipeau, MD
University of Wisconsin - Madison, USA
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate image
William Faubion, MD
Mayo Clinic, USA
07:30 - 08:30
Q&O Track 1: Media Fills
Q&O Track 1: Media Fills image
Adrian Gee, PhD
Baylor College of Medicine, USA
Aisha Khan, MS, MBA
University of Miami, USA
08:45 - 10:15
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs image
Allan B. Dietz, PhD (Chair)
Mayo Clinic, USA
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs image
Gil Van Bokkelen, PhD
Athersys, USA
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs image
Etienne Sokal, MD, PhD
Promethera, Belgium
10:15 - 10:45
Coffee Break
10:45 - 12:15
Oral Abstracts Session 1
Oral Abstracts Session 1 image
Patrick Hanley, PhD (Chair)
Children’s National Health System, USA
10:45 - 12:15
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Daniel Weiss, MD, PhD (Chair)
University of Vermont, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Tracey Webb, DVM, PhD (Chair)
Colorado State University, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Andrew Hoffman, DVM, DVSc, DACVIM
University of Pennsylvania School of Veterinary Medicine, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Kyla Ortved, DVM, PhD
University of Pennsylvania School of Veterinary Medicine, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Aimee Colbath, VMD, PhD, DACVS-LA
Michigan State University College of Veterinary Medicine, USA
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use image
Dori Borjesson, BA, DVM, MPVM, PhD
UC Davis School of Veterinary Medicine, USA
10:45 - 12:15
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene image
Lynn O’Donnell, PhD (Chair)
Ohio State University, James Cancer Hospital Columbus, USA
12:15 - 13:45
Lunch
12:30 - 13:30
Corporate Tutorial Hosted by Fresenius-Kabi
13:45 - 15:15
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Robert Deans, PhD (Chair)
BlueRock Therapeutics, USA
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Dan Kaufman, MD, PhD
University of California San Diego, USA
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Stephanie Protze, PhD
University of Toronto, Canada
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies image
Robert Deans, PhD
15:15 - 15:30
Coffee Break
15:30 - 17:00
Q&O Track 3: Stability
Karl Stasko, MPH (Chair)
Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Karl Stasko, MPH
Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Q&O Track 3: Stability image
Jackie Damen, PhD
Senior Scientific Advisor, Hematopoiesis, Canada
Q&O Track 3: Stability image
Rosemarie Bell, B.App.Sc Micro/Biochem MASM,
QIMR Berghofer Medical Research Institute/ Q-Gen Cell Therapeutics, Australia
15:30 - 17:00
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Laertis Ikonomou, PhD (Chair)
Boston University, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Peter Marks, MD, PhD
Center for Biologics Evaluation and Research, FDA, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Lynne Boxer, DVM
Center for Veterinary Medicine, FDA, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Ajay Kuriyan, MD, MS
Department of Ophthalmology, University of Rochester Medical Center, USA
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America image
Kristin Matthews, PhD
Rice University's Baker Institute for Public Policy, USA
15:30 - 17:00
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Mitchell Cairo, MD (Chair)
New York Medical College, USA
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Mitchell Cairo, MD
New York Medical College, USA
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Jeffrey Medin, PhD
Medical College of Wisconsin, USA
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells image
Paul Orchard, MD
University of Minnesota, USA
17:00 - 18:00
Corporate Symposium
18:00 - 18:30
Welcome Address
18:30 - 20:30
Welcome & Networking Reception
07:00 - 17:00
Registration
07:30 - 08:30
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications image
Kurt Gunter, MD (Chair)
Cell Medica Inc., USA
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications image
Peiman Hematti, MD
University of Wisconsin-Madison School of Medicine and Public Health, USA
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications image
Cynthia Molina
Triumvira, USA
07:30 - 08:30
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations image
Lizette Caballero, BS, MLS(ASCP)CM (Chair)
UCSF Blood and Marrow Transplant Lab, USA
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations image
Paul Eldridge, PhD
UNC Lineberger Comprehensive Cancer Center, USA
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations image
Olive Sturtevant, MHP, MT(ASCP)SBB
Dana-Farber CMCF, USA
07:30 - 08:30
Morning Session 3 – Meet the Experts: CAR T and other Cell “Vehicles”
Morning Session 3 –   Meet the Experts: CAR T and other Cell “Vehicles” image
Sarah Nikiforow, MD, PhD (Chair)
Dana-Farber Cancer Institute, USA
08:45 - 10:15
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Sarah Nikiforow, MD, PhD (Chair)
Dana-Farber Cancer Institute, USA
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Denis-Claude Roy, MD, FRCPC
Hopital Maisonneuve-Rosemont, Canada
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Lisa Butterfield, PhD
University of Pittsburgh Department of Medicine, USA
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs image
Sumithira Vasu, MBBS
Comprehensive Cancer Center, Ohio State University, USA
10:15 - 10:45
Coffee Break
10:45 - 12:15
Oral Abstracts Session 2
10:45 - 12:15
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy
Valkal Bhatt, PharmD, BCOP, BCPS (Chair)
Memorial Sloan Kettering Cancer Center, USA
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy image
Christina Bachmeier, PharmD, BCOP
Moffitt Cancer Center, USA
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy image
Rebecca Gonzalez, PharmD, BCOP
Moffitt Cancer Center, USA
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy image
Marian Dam, DNP, APRN
Moffitt Cancer Center, USA
10:45 - 12:15
Workshop 4: Optimizing Clinical Trials in Cellular Therapy
Workshop 4: Optimizing Clinical Trials in Cellular Therapy image
Denis-Claude Roy, MD, FRCPC (Chair)
Hopital Maisonneuve-Rosemont, Canada
Workshop 4: Optimizing Clinical Trials in Cellular Therapy image
Lauralyn McIntyre, MD, FRCPC, MSc
Ottawa Hospital Research Institute, Canada
Workshop 4: Optimizing Clinical Trials in Cellular Therapy image
Sarah Nikiforow, MD, PhD
Dana-Farber Cancer Institute, USA
Workshop 4: Optimizing Clinical Trials in Cellular Therapy image
Steven Devine, MD
CIBMTR, USA
12:15 - 13:45
Lunch
12:30 - 13:30
Corporate Tutorial
13:45 - 15:15
Q&O Track 5: ISCT-ASFA Joint Session – Current Concepts in Cell Collections: HPCs, CAR-T & Regulatory Oversight
Joseph Schwartz, MD, PhD (Co-Chair)
Columbia University, USA
Q&O Track 5: ISCT-ASFA Joint Session – Current Concepts in Cell Collections: HPCs, CAR-T & Regulatory Oversight image
Lizette Caballero, BS, MLS(ASCP)CM (Co-Chair)
UCSF Blood and Marrow Transplant Lab, USA
Q&O Track 5: ISCT-ASFA Joint Session – Current Concepts in Cell Collections: HPCs, CAR-T & Regulatory Oversight image
Donald Siegel, PhD, MD
Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, USA
Anand Padmanabhan, MD, PhD
Blood Center of Wisconsin, USA
Q&O Track 5: ISCT-ASFA Joint Session – Current Concepts in Cell Collections: HPCs, CAR-T & Regulatory Oversight image
Yvette Tanhehco, PhD, MD, MS
Columbia University Irving Medical Center, USA
13:45 - 15:15
Workshop 5: Engineering to Control Cell Environment during Processing
Workshop 5: Engineering to Control Cell Environment during Processing image
Erika Trauzzi (Chair)
Berkeley Lights Inc., USA
Workshop 5: Engineering to Control Cell Environment during Processing image
James Lim, PhD
Xcell Biosciences Inc., USA
Peter Beemiller
Berkeley Lights Inc., USA
Angelo Cardoso, MD, PhD
City of Hope, USA
13:45 - 15:15
Advanced Practice Professionals* (APP) Track Session 2: Responsibilities of the Investigator and the Lab in the investigation, communication and reporting of Adverse Events
Valkal Bhatt, PharmD, BCOP, BCPS (Chair)